HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to display Sunshine payment data

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like meals, travel, gifts, consulting and research

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

Next target for hep. C drugmakers: co-infections

Next target for hep. C drugmakers: co-infections

An international AIDS conference this weekend kicked off a new battle in the war against hepatitis C: demonstrating high cure rates in those who are co-infected.

CME commercial support cuts narrow

CME commercial support cuts narrow

The rate of decrease in industry's budget for continuing medical education (CME) slowed last year.

Industry trims support for CME

Industry reined in commercial support for CME in 2013—the sixth consecutive annual decrease—data released today by the ACCME show.

Study links Actos with delayed dementia

German healthcare data from 2004 through 2010 across a data set that included 146,000 patients shows dementia surfaced later among Actos patients.

FDA quicker on approval trigger than EU: study

The FDA began its drug review at a median time of 103 days sooner than the EMA. Being first, researchers found, often resulted in quicker approval.

Generics trigger wallet shock

Prices for some generics are rising, thanks to limited competition.

Healthcare organization makes big data bigger

Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.

Zohydro's second act

Zogenix is working on a less easily abused formulation of its controversial prescription painkiller.

CDC: US is biggest Rx opioid market

CDC: US is biggest Rx opioid market

The Centers of Disease Control reports that prescribers wrote enough painkiller prescriptions to give one bottle to every adult in the US in 2012.

Facebook's clinical trial

The networking site's emotion experiment rankles some in the science and political communities.

IMS to buy Cegedim CRM

IMS to buy Cegedim CRM

IMS is offering $520 million cash to add Cegedim's CRM and strategic data business. Cegedim says it will use the money to pay down debt.

Drug sales to hit $1T by 2020, researchers say

Drug sales to hit $1T by 2020, researchers say

EvaluatePharma's World Preview 2014 has pharma soaring to new lucrative heights in six years' time, buoyed by biologics and a formidable pipeline.

Vertex to submit CF drug combo to FDA this year

Vertex to submit CF drug combo to FDA this year

Phase III results showing improved lung function among cystic fibrosis patients using a combination of Kalydeco and lumacaftor means drugmaker Vertex is filing the two-part drug for FDA approval during the fourth quarter.

Sifting social media for the "why" behind Rx switching

Sifting social media for the "why" behind Rx switching

Platform lets pharma firms mine big data, and monitor whether millions spent on ad campaigns or medical education are having the desired effect

Triglycerides, not HDL, may be cardio bad guys

Gene mutations lead researchers to rethink ways to protect the heart.

Study finds Alzheimer's misunderstood

Study finds Alzheimer's misunderstood

An Alzheimer's Association survey finds 59% think the degenerative disease is just part of aging.

Study: Opioid deaths outnumber heroin-associated ones

Study: Opioid deaths outnumber heroin-associated ones

Researchers at Montreal's McGill University survey the explosion in prescription painkiller use and abuse.

Novartis says it buried studies

The drugmaker has told global regulators it failed to share 10,000 reported cases of side effects for a variety of its drugs.

Higher dose of Victoza helped patients drop weight

Higher dose of Victoza helped patients drop weight

Patients taking a high-dose form of Novo Nordisk diabetes drug Victoza saw an average weight loss of 5.9% of their body weight, data from a study show.

Seniors are major painkiller users

A USA today analysis shows Medicare painkiller prescriptions rose 30% between 2007 and 2012.

Patients paying more for diabetes medications

Patients paying more for diabetes medications

Yale researchers find patients are paying more money for newer diabetes medications as they gravitate towards insulin analogs, over human synthetic and animal insulin.

Researchers urge specialty Rx insurance plans

Researchers urge specialty Rx insurance plans

Researchers argue it makes economic sense to employ Value-Based Insurance Design plans for costly specialty medications.

Statins linked to less exercise, more diabetes

Two studies found two different facets of statin therapy—one found patients moved less a year after starting their regimens, and another that the drugs upped the diabetes risk for some.

Top opioid prescribers not pain specialists

Express Scripts said that family and internal medicine doctors were the top opioid prescribers between 2011 and 2012.

Doctors get political

A study shows doctors have been giving more political donations—and leaning heavily Democrat—since 1991.

Study: Using Avastin over Lucentis could save $18B

Study: Using Avastin over Lucentis could save $18B

Researchers say switching patients from Lucentis to Avastin eye diseases could save the government $18 billion.

ASCO highlights immuno-oncology challenges

ASCO highlights immuno-oncology challenges

The potential of immunotherapy is great, but the news from the 2014 medical meeting shows that great may not be gargantuan in terms of treatment reach.

FDA examines DTC close up

FDA examines DTC close up

The regulator's latest study will use eye-tracking tools.

FDA invests in clinical trial data

The regulator is allocating almost $38 million to improve data-guided decision-making.

WorldOne re-organizes, unifies around Sermo

WorldOne re-organizes, unifies around Sermo

The pharma market research major is working on unifying into one company with two main product lines, and is also in the process of a re-brand.

GSK drug fails in lymphoma bid

GSK drug fails in lymphoma bid

The companies announced Tuesday that Arzerra, already indicated for leukemia, failed to outdo Roche's Rituxan in the lymphoma setting.

BI, InterMune tout lung drugs

BI, InterMune tout lung drugs

Both companies revealed Phase-III data for idiopathic pulmonary fibrosis treatments. The progressive disease generally kills patients within three years of diagnosis.

Two more obesity meds circle Rx status

Gelesis is pouring money into its obesity "smart pill," and Novo reports weighty success among subjects taking liraglutide.

Bayer joins transparency push

The drugmaker announced Wednesday that researchers would be able to access clinical trial data.

GSK heart drug misses endpoint

GlaxoSmithKline announced Tuesday its Phase-III drug from the Human Genome Sciences acquisition failed to hit its primary endpoint.

Lilly basal poses uncertain threat to Lantus

Lilly basal poses uncertain threat to Lantus

Phase-III results for Eli Lilly basal insulin peglispro showed superior blood sugar reduction vs. Sanofi's Lantus in trials, but a number of safety issues could hurt its appeal.

BI opens up data files

The company announced Monday that researchers will be able to seek out clinical trial data going back to 1998.

Survey finds pharma and payers not aligned

Survey finds pharma and payers not aligned

An EY report finds that pharma is not only failing to give payers the right type of drug data, but that industry has a lot of trust-building to do before they will accept it.

Women's Health Initiative touts ROI

According to an analysis of final data from one of the WHI's trials, each dollar received results in a net economic value of $140.

Cancer drug marches toward filing

Merrimack Pharma said its candidate for pancreatic cancer increased overall survival, and that it plans to file applications in the US and EU this year.

Bloomberg scrutinizes drug pricing

An analysis by Bloomberg today shows why drug pricing "keeps defying the law of gravity."

BMS teases immunotherapy filing in Q1 results

BMS teases immunotherapy filing in Q1 results

Sales slipped 1% for the quarter, but the drugmaker couched the financials with news from its much-watched effort in immuno-oncology: that it will wrap its nivolumab filing by the end of this year.

Research conflicts not limited to pharma

A piece about obesity and Coca-Cola shows the widespread nature of conflict-of-interest discussions and concerns about the sway that honoraria and other goodies may exert on researchers.

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also reaped blockbuster sales for Gilead.

Medicare numbers trigger physician anger

Wednesday's coverage of doctor pay roiled physicians who say the CMS data set oversimplifies payment information and skews reality.

Merck looks poised to challenge Gilead

Merck looks poised to challenge Gilead

Phase-II results indicate Merck's all-in-one HCV oral could put pressure on Gilead.

Sunshine data highlights major billers

Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.

Diabetes costliest among non-specialty Rx

Diabetes costliest among non-specialty Rx

Express Scripts said treatments for diabetes are the most expensive of the traditional medications, while specialty drugs are eating up a significant portion of total drug spend.

Study links patient confidence to Rx adherence

Study links patient confidence to Rx adherence

Researchers found a correlation between patients feeling involved and how well they stick—if they stick—to their medication regimens.

Alkermes to submit schizophrenia med this year

Phase-III results prompted the drugmaker to pursue a third-quarter filing.

Lilly's CDK 4/6 inhibitor a cancer contender

Lilly's CDK 4/6 inhibitor a cancer contender

Analysts say the Indianapolis, IN, drugmaker's Phase-I results show CDK 4/6 inhibitors will have a role in breast cancer treatment and that Pfizer's palbociclib will not clear the field.

Pfizer palbociclib news divides investors

Pfizer palbociclib news divides investors

Sunday's data readout has divided the Street between the enthusiastic and the disappointed. The key reason: progression-free survival gains were not as high as anticipated.

Health reform spurs Rx growth, data show

Health reform spurs Rx growth, data show

The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.

Sanofi reports on Phase-II PCSK9 trial

The drugmaker saw positive results in demonstrating LDL reductions in Japanese patient populations.

Trials confirm potent efficacy of PCSK9s

Trials confirm potent efficacy of PCSK9s

Detailed Phase-III results from several PCSK9 candidates confirm the clinical ability of the newest class of cholesterol-lowering treatments.

Merck diversifies its Big Data agenda

Merck diversifies its Big Data agenda

Merck has broadened its analytics approach to include team-ups with a slate of organizations at the intersection of Big Data and health IT.

Possible Zohydro competitor surfaces

Possible Zohydro competitor surfaces

A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.

EHR use up 10%, as small practices tame data crunch

EHR use up 10%, as small practices tame data crunch

A report of over 270,000 US medical sites signals that EHR adoption is no longer a luxury reserved for hospitals and health systems.

Prevnar 13 hits goals, but impact is uncertain

Prevnar 13 hits goals, but impact is uncertain

Pfizer hit its endpoints for preventing pneumonia among the elderly, but the data may not be robust enough to spur vaccination.

Adults increasingly using ADHD medications

Adults increasingly using ADHD medications

Express Scripts notes that these prescriptions may not, in fact, be for ADHD.

Nexavar fails recurrence target

Nexavar fails recurrence target

Bayer and Amgen's Onyx subsidiary announce an oncology drug failed a Phase-III trial goal among liver cancer patients.

Study shows sample-drug adherence link

Study shows sample-drug adherence link

A survey of patients found greater prescription drug adherence among patients who received a free 30-day sample in addition to a prescription.

New FDA Twitter feed has diverse following

@openFDA and its related website launched February 27.

AbbVie's all-oral HCV combo shines in trial

AbbVie's all-oral HCV combo shines in trial

Data presented at a conference yesterday suggest AbbVie's all-oral regimen may be more effective than Gilead's at curing the virus in certain patients, but will it confer an edge?

Novartis enhances data access

The drugmaker says researchers will be able to view patient-level data and promises less jargon-filled summaries by year-end.

FDA approves sNDA for Xeljanz

The new label will reflect the RA pill's superiority to methotrexate and placebo in inhibiting the progression of structural joint damage.

Lilly's GLP-1 contender takes a step forward

Lilly's GLP-1 contender takes a step forward

Phase-III results, top-lined today, show Lilly's investigational GLP-1 drug is well-positioned to eat into the multi-billion-dollar diabetes market now dominated by Novo Nordisk.

Pfizer Prevnar data could boost Rx numbers

Pfizer Prevnar data could boost Rx numbers

The drugmaker revealed efficacy data that analysts say could prompt the health agencies to emphasize adult vaccination.

Lilly's ramu' has squamous, non-squamous potential

Lilly's ramu' has squamous, non-squamous potential

The drugmaker was scant on details, but Phase-III ramucirumab results among non-small cell lung cancer patients showed increased overall and progression-free survival vs. placebo.

Study finds doctor reviews matter to some extent

Study finds doctor reviews matter to some extent

A report published by JAMA indicated that online reviews sway a percentage of patients, but that personal recommendations hold more weight.

Janssen signs onto Yale data-sharing project

The school will act as an independent panel for the drug maker, reviewing requests from investigators for access to anonymized, clinical-trial data.

Pitting Big Data against nonadherence

Pitting Big Data against nonadherence

A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.

Ph.III results a boost for Amgen in PCSK9 race

Ph.III results a boost for Amgen in PCSK9 race

Positive results from a Phase-III trial edge Amgen's evolocumab closer to approval, though it's still behind rivals in the PCSK9 race.

IMS to go public, says acquisitions possible

IMS to go public, says acquisitions possible

The data and analytics giant is looking to launch an IPO. The company, which is the subject of an antitrust suit, said in its prospectus that it anticipates future acquisitions.

Amgen bone-builder bests older meds: trial

Amgen bone-builder bests older meds: trial

Mid-stage data show the drug, romosozumab, was associated with significant increases in bone mineral density compared to Lilly's Forteo and off-patent Fosamax.

The year's most popular stories

The year's most popular stories

Our year-end list captures the 10 that sparked heaviest interest.

Kalydeco misses trial endpoint, though some benefit

Kalydeco misses trial endpoint, though some benefit

Kalydeco failed to hit its primary endpoint of significantly improving lung function in a subset of CF patients, but some did show a benefit.

Data arm Gilead for next stage of HCV race

Data arm Gilead for next stage of HCV race

Sovaldi is already approved for most patients with HCV, but its marketer may have earned itself some breathing room against rivals in the next stage of the all-oral hep. C arms race.

Patients sound off on helping pharma find new molecules

Patients sound off on helping pharma find new molecules

A recent poll shows a strong desire among web-savvy patients to play a more active role in medical research.

Sanofi's heir to Lantus meets endpoint in trials

Sanofi's heir to Lantus meets endpoint in trials

Sanofi top-lined positive clinical data today from its investigational basal insulin, as it seeks to defend its position in this fast-growing segment.

ADHD rise spurs diagnostics firms

ADHD rise spurs diagnostics firms

Research suggests ADHD is becoming a regular fixture in adolescence. At the same time, publishers and startups have developed increasingly complex tools to separate patients from abusers.

Poll: Statin use will grow modestly

Poll: Statin use will grow modestly

A poll indicates new cholesterol guidelines won't shake up the statin market in 2014.

E-prescribing systems not so pharma friendly

E-prescribing systems not so pharma friendly

A study points out barriers to e-prescribing pharma products and shows how doctors rate various EHRs.

Amgen PCSK9 drug passes safety test

New results from its Phase II safety trial show the LDL-cholesterol lowerer was not associated with a major increase in adverse events vs. standard of care.

Small patient majority supports risky Sanofi MS drug: poll

Small patient majority supports risky Sanofi MS drug: poll

Most patients would advise today's FDA Lemtrada panel to allow doctors to gauge the drug's risk-benefit profile, although there was strong sentiment on either side of the issue.

GSK misses on late-stage CV drug

GSK misses on late-stage CV drug

An investigational cardiovascular heart drug failed to reduce the risk of heart attack or stroke, a miss which some on Wall Street say raises questions about the drugmaker's ability to deliver in late-stage trials.

Lemtrada's future in doubt after reviewers flag safety issues

Lemtrada's future in doubt after reviewers flag safety issues

Safety reviewers' reservations about the MS drug's risk profile, unveiled in briefing documents ahead of an ad-com meeting, suggest it won't be smooth sailing for the drug in the US.

Genotype-1 hep. C race heats up

Genotype-1 hep. C race heats up

Data released at the Boston meeting of the American Association for the Study of Liver Diseases hints at an upcoming Gilead-Merck brawl.

Health apps come up short in study

Health apps come up short in study

Researchers found that most healthcare apps have limited functionality, don't serve patients with multiple needs, and taper off when support is needed most. No wonder adoption is low.

Study says DPP-IV benefits may go beyond diabetes

Researchers say the drug class could be linked to a lower autoimmune risk among diabetics.

Pediatricians want greater condom access

The AAP says greater access and education are critical in curbing STIs.

FDA panel endorses Gilead, Janssen hep. C drugs

It was a 15-0 vote for Gilead's sofosbuvir in hep. C. The expedited PDUFA date: Dec. 8. Janssen's simeprivir was endorsed the day before.

Mobile makes users more likely to switch brands: survey

Mobile makes users more likely to switch brands: survey

Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.

Good news/bad news for Merck's pipeline

Word came of Breakthrough Designation for an HCV hopeful, a day after a hiccup in a heart drug trial.

Poll suggests oncologists already using GSK melanoma drugs off-label

A report says oncologists may be using GSK's Tafinlar and Mekinist together in a non-FDA approved combination therapy.

Email Newsletters